Cue Health Appoints David Tsay, MD, PhD, as Chief Medical Officer
Cue Health Inc. (“Cue”) ( Nasdaq: HLTH), a healthcare technology company, today announced that it has appointed David Tsay, MD, PhD, as its Chief Medical Officer. Dr. Tsay comes to Cue with more than 20 years of experience in clinical medicine, research, and health technology. Most recently, Dr. Tsay served at Apple, where he led an Apple Health clinical team in developing new Health products, including FDA-cleared products in cardiovascular health.
As Chief Medical Officer, Dr. Tsay will help define future Cue diagnostic products and services. Dr. Tsay will also lead engagement across a wide range of healthcare stakeholders, driving communication, collaboration, and ecosystem alignment in support of Cue’s healthcare initiatives.
Prior to Apple, Dr. Tsay served as Associate Chief Transformation Officer at New York-Presbyterian (NYP), one of the nation’s most comprehensive academic healthcare delivery systems. He led digital transformation initiatives for NYP, including overseeing enterprise teams for data science, business intelligence, artificial intelligence, automation, and digital web/mobile technologies. During his tenure at NYP, Dr. Tsay also served as an Assistant Clinical Professor of Medicine at Columbia University Medical Center. He was previously a founding team member for NYP OnDemand, a comprehensive suite of digital health services.
“We are delighted to have Dr. Tsay join us as our Chief Medical Officer. We believe Dr. Tsay will play a key role in shaping the advanced healthcare technologies we are creating at Cue, where diagnostics and software-supported health journeys can lead to better clinical outcomes across a variety of disease categories,” said Ayub Khattak, Chairman and CEO of Cue Health. “Dr. Tsay has the clinical experience, proven leadership ability, and key relationships to make a meaningful and lasting impact at Cue as well as in the lives of the patients and providers we serve.”
“I look forward to working alongside Cue’s executive leadership team as the company’s products evolve into a more comprehensive platform that empowers stakeholders across the healthcare ecosystem with faster and more accurate diagnostic information,” added Dr. Tsay. “The democratization of diagnostic testing can not only transform care paradigms but also ultimately help improve health outcomes.”
Dr. Tsay received his BA in Computer Science and Physics from Columbia University College, and subsequently his MD and PhD degrees from Columbia University College of Physicians and Surgeons. He is board certified in internal medicine and cardiology and holds active medical licenses in both California and New York.
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more